Dr Amar Kishan (Radiation Oncologist, UCLA, USA), made lots of headlines recently when he presented data from the phase II randomised LUNAR trial of SABR +/- LuPSMA in patients with oligometastatic prostate cancer. So we were very happy when he turned up in Melbourne recently and popped into the GU Cast studio for a chat. We discuss metastasis-directed therapy and bring up our favourite Pokemet analogies, and ask should we not just be offering these patients and ADT/ARPI doublet?! 

Regular hosts Declan Murphy and Renu Eapen, also joined by Prof Wee Ong, Radiation Oncologist at Alfred Health in Melbourne. 

This is a Themed Podcast supported by our Gold Partners, Johnson & Johnson. 

Even better on our YouTube channel